BRAF and melanoma: There are many drugs used clinically to inhibit the MAPK pathway such as emurafenib and dabrafenib inhibitors of B-RAF, which were approved in 2011 and 2013, respectively, for clinical practice in melanoma, whereas MEPK inhibitor trametinib was approved in 2014 for the treatment of advanced BRAF-mutated melanoma, alone and in combination with dabrafenib [101].